64x Bio is discovering new mammalian cell lines to transform cell and gene therapy manufacturing. To develop and manufacture cell therapies, cell lines that are easy to manipulate, engineer and grow are required. 64x Bio is using their VectorSelect platform to generate highly optimized cell lines that meet the requirements for production of cell therapies. In particular, 64x Bio is enhancing the efficiency of cell lines to manufacture viral vectors that improve manufacturing capacity and reduce overall cost. This involves high-throughput genome engineering, screening technologies and 64x Bio’s proprietary genetic barcoding method that connects information of viral vector productivity back to the parent cell which produced it.

<p>64x Bio is discovering new mammalian cell lines to transform cell and gene therapy manufacturing. To develop and manufacture cell therapies, cell lines that are easy to manipulate, engineer and grow are required. 64x Bio is using their VectorSelect platform to generate highly optimized cell lines that meet the requirements for production of cell therapies. In particular, 64x Bio is enhancing the efficiency of cell lines to manufacture viral vectors that improve manufacturing capacity and reduce overall cost. This involves high-throughput genome engineering, screening technologies and 64x Bio’s proprietary genetic barcoding method that connects information of viral vector productivity back to the parent cell which produced it.</p>


64x Bio

64x Bio Raises $55M To Advance Gene Therapy Platform

 64x Bio Raises $55M Series A 

 All 59 startups that launched today at Y Combinator’s S18 Demo Day 2 

Harvard offshoot 64x Bio nets $55M in series A funding to expand cell production tech - FiercePharma

🥕🥕 From Tunisia to the heart of Y Combinator, I had a blast learning from Lexi Rovner (64x Bio), Alex Levy (Atmo), Banks Hunter (Charge Robotics), and the awesome Jared Friedman. 
Grateful for the opportunity to learn from their journey in building deep tech startups.

#YC #YCombinator #deeptech #startup

64x Bio Lands $55 Million for Gene-Therapy Tech - The Wall Street Journal

Here is the 10-slide deck a new biotech company addressing a critical gene- therapy bottleneck used to raise $55 million in just a few months

 64x Bio Raises $55 Million Series A Financing to Advance Cell Line Engineering Platform for Gene Therapy Manufacturing 

Catch 64x Bio at SynBioBeta in San Jose, this week! Our CEO & co-founder Lexi Rovner will be speaking on two panels on Wednesday 5/7.

Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort - Business Wire

 At Y Combinator, Startups Manage Molecules Rather Than Code 


              The State of Cell and Gene Therapy 2024 ,Wed, Jan 24th, 2024 @ 11:00 AM, Mary Ann Liebert, Inc. publishers
            

The State of Cell and Gene Therapy 2024 - Genetic Engineering & Biotechnology News

🚀 2 Months Until SynBioBeta 2025!

We’re excited to announce new speakers joining SynBioBeta 2025, the leading synthetic biology conference.

New Speaker Lineup:
🔹 Cynthia Hong – Novartis, Director, Search & Evaluation
🔹 Jeffrey Tibbetts – Symbiont Labs, CEO
🔹 Lexi Rovner – 64x Bio, CEO & Co-founder
🔹 Karin Conde-Knape – Novo Nordisk A/S, Senior Vice President
🔹 Ronald Mathae – Evonik Operations GmbH, Director Global Project Management
🔹 Ashley Zehnder – Fauna Bio, CEO
🔹 Kosuke Fujishima – Institute of Science Tokyo (Science Tokyo), Associate Professor
🔹 Gul Dolen – University of California, Berkeley, Professor
🔹 Daniel Bryan Goodman – University of California, San Francisco, Postdoctoral Fellow
🔹 Keith Murphy – Attune Neurosciences, Inc., Co-founder & CIO
🔹 Hanadie Yousef – Juvena Therapeutics, CEO & Co-founder
🔹 Patrick Malone, MD PhD – KdT Ventures, Partner

Join us May 5-8, 2025, in San Jose, California, for key industry insights and networking opportunities.

🔗 Register now! 

#SynBioBeta2025 #SyntheticBiology

 Mammalian cells and methods for engineering the same 

Was honored to moderate a panel on cell and gene therapies at the #biotechshowcase during JPM week in SF - I learned a lot about how these long promised technologies are finally here, although we’re just at the beginning - we also discussed the challenge of creating companies and making them work, and issues around cost, safety, and regulations. Thanks to my panelists: 

Paul Bresge  - CEO, Ray Therapeutics, which is restoring sight to the blind using gene therapy;

Daniel Oliver - CEO, Rejuvenate Bio, a George Church  company that among other things is working to reverse aging; 

Nabiha Saklayen  - CEO & Founder, Cellino Biotech, which is radically scaling precision cellular cengineering tech; 

Lexi Rovner  - CEO, 64x Bio, another George Church spin out that uses advanced tech to create cell lines for viral vectors

🎗️Ohad Karnieli   - Founder & CEO , Adva Biotechnology, a cell platform company

Thanks to Sara Jane Demy  and Sara Pinto  and the @biotech showcase team!

We’re excited to share the news of our $55M series A today!

https://lnkd.in/giZcFMyU

Power Players: These Are the Leading Biotech Seed Investors - Business Insider

The Week in Bio 21/1/2022 - substack.com

Academic innovators have driven groundbreaking technologies like CRISPR, gene therapies, CAR T, and mRNA. The handoff to industry is allowing such discoveries to reach patients, but some of these transformations must overcome limitations that cap their use.

At #BioCenturyGrandRounds, the Modality Groundbreaker Session spotlighted potential solutions and guide drug developers on prioritizing innovations for efficient patient treatment:
➤ The heyday of AAV engineering is here: Will it deliver?
➤ The regenerative moment: Are iPSCs poised to reshape the cell therapy toolbox?
➤ Maximizing the impact of gene editing: Incremental improvements, or leaps to newer technologies?
➤ Souping up cancer cell therapies: Is the juice worth the squeeze?

Registration is available on-site at Four Seasons Nashville, or register for a digital pass to watch recordings of the sessions at https://lnkd.in/gmhZ75vm.

Thank you to our Grand Rounds II: Modality Groundbreakers panelists and moderators:
Andrew Bellinger, Verve Therapeutics
Zandy Forbes, MeiraGTx
Erin Kimbrel, Astellas Pharma
Samuel Lynch, Vanderbilt University Medical Center
Marinna Madrid, PhD, Cellino Biotech
Clare Murray, Life Edit Therapeutics
Greg Newby, The Johns Hopkins University
Stephanie Oestreich, myeloma investment fund
Deborah Palestrant, 5AM Ventures
Becky Pferdehirt, PhD, Andreessen Horowitz
Lexi Rovner, 64x Bio
Krishnendu Roy, Vanderbilt University
Florencia Pereyra Segal, MPM BioImpact
Henning Stennicke, Spur Therapeutics

George Church backs a startup solution to the massive gene therapy manufacturing bottleneck

I'm beyond thrilled to announce Northwestern's Querrey InQbation Lab FoundHer Stories 2024 series highlighting inspiring women scientist entrepreneurs who have spun out startups from their academic research. 

Join us for virtual monthly fireside chats with these trailblazing entrepreneurs
as they share their startup stories and advice to first-time technical founders.

So honored to chat with these rockstars! Tina Boville (Aralez Bio), Peyton Greenside (BigHat Biosciences), Lexi Rovner (64x Bio), Elizabeth Wood (JURA Bio, Inc.), Marinna Madrid, PhD (Cellino), Janice Chen (Mammoth Biosciences), Mariana Matus, PhD (Biobot Analytics), Nishita Deka (Sonera)

Register here: https://lnkd.in/efvCGDgC

#startupstories #womenentrepreneurs #womeninstem #academicinnovation

How Church and Langer Make the Impossible Possible - Genetic Engineering & Biotechnology News

A George Church spinout fighting the viral vector bottleneck in cell and gene therapy lands $55M - Endpoints News

64x Bio’s iterative solutions to vector manufacturing pain points - BioCentury

A George Church spinout fighting the viral vector bottleneck in cell and gene therapy lands $55M​

64x Bio Lands $55 Million for Gene-Therapy Tech

64x Bio Raises $55M To Advance Gene Therapy Platform - Crunchbase News

64x Bio's iterative solutions to vector manufacturing pain points​

64x Bio Raises $55 Million Series A Financing to Advance Cell Line Engineering Platform for Gene Therapy Manufacturing - Business Wire

64x Bio Lands $55 Million for Gene-Therapy Tech - WSJ

Pitch Deck: 64x Bio Raises $55 Million for Cell, Gene Therapy Tools. - Business Insider

 The top 10 startups from Y Combinator’s Demo Day S18 Day 2 

64x Bio emerges from stealth to drive an evolution in cell and gene therapy manufacturing

 Engineered organisms and uses thereof in the production of biologics, reagents, … 

The 64x Bio team is in San Francisco for the J.P. Morgan 42nd Annual Healthcare Conference, and is excited to connect with partners, colleagues, and friends!
 
If you're in San Francisco for the conference, we're looking forward to discussing our latest progress, our plans for 2024, and exploring new partnership opportunities. Reach out to us at bd@64xbio.com.
 
The following members of our team are attending:
 
Lexi Rovner, CEO & Co-founder
Farhad (Seyyedhassan) Paylakhi, VP of R&D & Co-founder
 
We're looking forward to seeing you here!

Harvard offshoot 64x Bio nets $55M in series A funding to expand cell production tech

It's been an incredible start to #JPM2025 Healthcare Conference Week! 🎤

Cellino is thrilled to begin the week in #SanFrancisco, contributing to discussions on the future of personalized regenerative medicine. Our CEO & Co-Founder, Nabiha Saklayen, spoke on the "Cell & Gene Therapy: Moving Beyond Discovery and Into the Patient" workshop at #BiotechShowcase, co-produced by Demy-Colton and EBD Group.

Nabiha shared our approach to automating and scaling autologous cell therapies, alongside other industry leaders:

🔹 Paul Bresge, CEO, Ray Therapeutics, Inc.
🔹 Daniel Oliver, CEO, Rejuvenate Bio
🔹 Lexi Rovner, CEO, 64x Bio
🔹 🎗️Ohad Karnieli, Founder & CEO, Adva Biotechnology
🔹 David Ewing Duncan, Journalist, Author, Researcher

Thank you to everyone who attended and connected with us! 

#JPMorganHealthcare #Innovation #Biotech #Healthcare #Biomanufacturing #PersonalizedMedicine #RegenMed #YourCellsYourCure #CellinoBio

64x Bio Raises $55 Million Series A Financing to Advance Cell Line Engineering Platform for Gene Therapy Manufacturing

See the presentations that cutting-edge biotech companies have used to raise millions from top investors - Business Insider

64x Bio

Business:

About: